Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020092848 - METHODS FOR TREATMENT USING CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN

Publication Number WO/2020/092848
Publication Date 07.05.2020
International Application No. PCT/US2019/059271
International Filing Date 31.10.2019
IPC
C07K 16/30 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
C07K 16/2878
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2878against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
C07K 2317/33
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
C07K 2317/34
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
C07K 2317/622
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
60characterized by non-natural combinations of immunoglobulin fragments
62comprising only variable region components
622Single chain antibody (scFv)
Applicants
  • JUNO THERAPEUTICS, INC. [US]/[US]
  • MEMORIAL SLOAN KETTERING CANCER CENTER [US]/[US]
Inventors
  • SATHER, Blythe D.
  • SMITH, Eric L.
  • TAREEN, Semih
  • CHEN, Aye
  • DE IMUS, Cyr
  • HESS, Erik
  • OLSHEFSKY, Audrey
  • PONKO, Stefan
  • STIRNER, Mariana Cota
Agents
  • AHN, Sejin
  • POTTER, Karen
  • RICE, Rachel
  • MULLEN III, James J.
  • SCHMIDT, Jeffrey W.
  • YIN, Bu
Priority Data
62/754,57701.11.2018US
62/774,16730.11.2018US
62/774,85603.12.2018US
62/777,06607.12.2018US
62/845,81709.05.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS FOR TREATMENT USING CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN
(FR) MÉTHODES POUR LE TRAITEMENT AU MOYEN DE RÉCEPTEURS ANTIGÉNIQUES CHIMÉRIQUES SPÉCIFIQUES DE L'ANTIGENE DE MATURATION DES LYMPHOCYTES B
Abstract
(EN)
Provided herein are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain plasma cell malignancy. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs) specific to B-cell maturation antigen (BCMA). In some embodiments, the methods are for treating subjects with multiple myeloma (MM). Also provided are genetically engineered cells containing such BCMA-binding receptors for uses in adoptive cell therapy.
(FR)
L'invention concerne des méthodes de thérapie cellulaire adoptive impliquant l'administration de doses de cellules pour le traitement de maladies et d'affections, y compris certaines tumeurs malignes de cellules plasmatiques. Les cellules expriment généralement des récepteurs recombinants tels que des récepteurs d'antigènes chimériques (CAR) spécifiques de l'antigène de maturation des lymphocytes B (BCMA). Dans certains modes de réalisation, les méthodes sont destinées au traitement de sujets atteints de myélome multiple (LNH). L'invention concerne également des cellules génétiquement modifiées contenant de tels récepteurs de liaison à BCMA destinées à être utilisées dans une thérapie cellulaire adoptive.
Latest bibliographic data on file with the International Bureau